7 citations
,
December 2013 in “The Journal of Dermatology” This article is a letter to the editor discussing hair graying and loss potentially induced by imatinib mesylate, but it does not provide new research results.
2 citations
,
February 2021 in “Indian Dermatology Online Journal” This case report describes the first instance of classical lichen planopilaris with atrophic lichenoid plaques developing in a Blaschko-linear pattern due to imatinib treatment in a patient with chronic myeloid leukemia.
December 2023 in “Journal of clinical medicine” This study reports the case of an elderly patient with a keratosis pilaris-like skin eruption after beginning treatment with imatinib for chronic myeloid leukemia, discussing similar skin reactions to BCR-ABL inhibitors and exploring potential mechanisms behind these adverse cutaneous reactions.
508 citations
,
June 2009 in “Current drug metabolism” This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.
182 citations
,
November 2017 in “Molecular Aspects of Medicine” This review discusses various therapeutic strategies targeting platelet-derived growth factor signaling in diseases like cancer and atherosclerosis, and evaluates existing treatments without presenting new clinical data.